Key Takeaways

• California’s Corporate Practice of Medicine doctrine applies to every non-licensee buyer of a treatment business, not only to private equity or hedge fund buyers.
• The clinical entity must be a physician-owned professional corporation under Cal. Corp. Code § 13401.5. A non-licensee cannot buy the shares of a California medical corporation because § 13407 makes any share transfer to a disqualified person void.
• Non-licensee buyers acquire treatment businesses through an asset purchase in which a physician-owned PC acquires the clinical assets and the buyer’s MSO acquires the non-clinical assets, with a Management Services Agreement governing the relationship going forward.
• SB 351 and AB 1415 (both effective January 1, 2026) add contract restrictions and pre-transaction notice obligations that reach deal structuring and timing, particularly for buyers using acquisition vehicles or with private equity or hedge fund capital in the stack.
• Recent Attorney General enforcement (culminating in the June 2026 Carbon Health settlement) has imposed personal civil penalties on non-licensee owners and identified specific MSA arrangements the AG considers per se impermissible.
• “It’s all cash pay so CPOM doesn’t apply” is a myth. Payor mix is not a CPOM defense.

If you are not a California-licensed physician and you want to buy a med spa, an IV hydration clinic, a hyperbaric business, a ketamine practice, a GLP-1 weight-loss clinic, or another business that treats patients, you cannot acquire it the way you would a coffee shop or a marketing agency. California’s Corporate Practice of Medicine (CPOM) doctrine and the Moscone-Knox Professional Corporation Act reserve ownership of businesses that render medical services to licensed physicians, with narrow, specific exceptions. Non-licensee buyers reach the same commercial outcome through a different structure — the friendly-PC + Management Services Organization (MSO) model, but the deal has to be built for that structure from the first conversation with the seller, not retrofitted after closing.

Getting the structure right protects the buyer’s investment, protects the physician partner, and keeps the practice operating without disruption. Getting it wrong exposes everyone involved to civil penalties, contract voidability, payor recoupment, and — as recent California Attorney General enforcement has made clear, personal liability for the non-licensee owner.

Why Non-Licensees Cannot Simply Buy a California Treatment Business

The starting point is the doctrine, not the deal.

California’s Corporate Practice of Medicine doctrine — grounded in Business & Professions Code §§ 2052 and 2400, the Moscone-Knox Professional Corporation Act (Corp. Code §§ 13400 et seq.), and Medical Board of California guidance, prohibits unlicensed individuals and entities from owning or controlling the practice of medicine. The doctrine has been part of California healthcare law for decades, and it applies to every non-licensee: a solo entrepreneur, a family office, a strategic operator, a franchise system, and (as the new SB 351 makes explicit) private equity groups and hedge funds. The doctrine does not care whether the buyer is well-intentioned or well-capitalized. It cares about who owns and controls the entity that treats patients.

Two Corporations Code provisions define the practical constraints:

Cal. Corp. Code § 13401.5 requires California medical corporations to be at least 51% owned by licensed physicians, with a limited allied-professional minority. No unlicensed person may hold any shares of a medical corporation.

Cal. Corp. Code § 13407 goes further: any share transfer to a disqualified person is void. Disqualified shareholders’ shares must be transferred back to the corporation or to a qualified shareholder within statutory timeframes. This is why a non-licensee cannot buy the shares of an existing California medical corporation. The transfer is not merely voidable at some future regulator’s discretion — it is void by operation of statute.

Cal. Corp. Code § 17701.04(e) closes the other obvious workaround: a California LLC cannot render professional services. An LLC cannot own a medical practice, cannot bill patients for medical services, and cannot employ clinical staff to deliver those services. If the target the buyer is looking at operates through an LLC that treats patients, the seller has been operating out of compliance — a diligence finding the buyer needs to catch early, not inherit after closing.

The result: a non-licensee buyer who wants a California treatment business needs a physician-partner, a different entity structure, and a different transaction architecture.

The Friendly-PC + MSO Model in Practice

The compliant structure has two entities:

The Professional Corporation (PC). A California medical corporation formed under Cal. Corp. Code § 13401.5, owned by a licensed physician (or a group of physicians, if applicable). The PC holds the license, the patient records, the payor enrollments, and the clinical authority. The PC employs the physicians, physician assistants, nurse practitioners, RNs, and other clinical staff. All patient billing runs through the PC.

The Management Services Organization (MSO). A separate entity — typically an LLC — owned by the non-licensee buyer. The MSO provides everything that is not the practice of medicine: real estate and leasehold, non-clinical staff, marketing, technology and billing infrastructure, HR and payroll administration, purchasing, IT, business development, and equipment.

The two entities are connected by a Management Services Agreement (MSA). The MSA specifies the non-clinical services the MSO provides, the management fee (flat, cost-plus, or percentage-of-revenue), and — critically, the exclusive control the PC retains over clinical decisions and patient records. Percentage-of-revenue fees are lawful in California under B&P § 650(b) and the California Court of Appeal’s holding in Epic Medical Management, LLC v. Paquette, 244 Cal. App. 4th 504 (2015), provided the fee is supported by fair-market-value documentation and does not translate into MSO control over clinical decisions. The MSA is the central operating document of the friendly-PC + MSO structure. It is also the document the Attorney General reads first when the AG examines a friendly-PC arrangement.

The structure works. What makes it work is not the label on the entities — it is the operational separation the MSA documents and the parties actually maintain. Where the MSO exercises functions the AG considers clinical (equipment selection tied to clinical protocols, hiring and firing of clinicians based on clinical performance, control over provider compensation calibrated to clinical decisions), the label of “MSO” does not save the arrangement.

What SB 351 and AB 1415 Change for 2026

Two California statutes took effect January 1, 2026, and both reach deal structuring and timing for non-licensee buyers of treatment businesses.

SB 351 (Ch. 409, Stats. 2025) codifies the CPOM doctrine’s core prohibitions against interference with clinical decision-making, with statutory teeth specifically directed at private equity groups and hedge funds. SB 351 also voids non-compete and non-disparagement clauses in employment agreements between a physician and a PE/hedge fund-affiliated MSO or PC, with carve-outs for (a) otherwise-enforceable sale-of-business non-competes under B&P § 16601 and (b) confidentiality of material nonpublic information. The California Attorney General is authorized to enforce SB 351 through injunctive relief and equitable remedies, with attorney’s fees and costs recoverable.

Two points a buyer needs to internalize. First, SB 351’s PE/hedge fund targeting is statutory-language-specific, but the underlying CPOM doctrine — enforced through B&P §§ 2052/2400, § 17200 (the Unfair Competition Law), and the Medical Board’s disciplinary authority over any physician involved, applies to every non-licensee owner regardless of capital source. Second, existing arrangements are not grandfathered: contract provisions that violate SB 351 are void by operation of law on January 1, 2026, whether they were signed in 2020 or 2025.

AB 1415 (Ch. 641, Stats. 2025) adds a category of “noticing entities” to the Office of Health Care Affordability’s material-change-transaction notice regime under the Health Care Quality and Affordability Act. The new noticing entities include private equity groups, hedge funds, MSOs, newly-created business entities formed to enter into transactions with health care entities, and entities that own, operate, or control a provider. Noticing entities must provide at least 90 days’ advance written notice to OHCA before a material change transaction, and OHCA may waive review or initiate a Cost and Market Impact Review that can extend closing timelines by months.

OHCA released proposed AB 1415 implementing regulations on May 15, 2026. The proposal set a 5% ownership threshold for private equity and hedge fund transactions and added a real-estate sale-leaseback trigger, among other technical details. The proposed regulations were open for informal comment through June 11, 2026, discussed at the OHCA Board meeting on June 24, 2026, and were expected to proceed to emergency rulemaking in July 2026 with a projected August 2026 effective date. Confirm the current status at hcai.ca.gov before finalizing a deal structure that turns on AB 1415 thresholds.

For most single-clinic, non-institutional buyer deals, the AB 1415 notice will not trigger. For buyers using acquisition vehicles, rolling up multiple locations, or bringing PE or hedge fund capital into the stack, AB 1415 belongs on the deal timeline from the LOI.

Recent Enforcement: The Non-Licensee Buyer’s Reality Check

The California Attorney General’s 2026 enforcement pattern deserves attention because it changed the practical stakes for non-licensee buyers.

On March 30, 2026, the AG filed an amicus brief in Art Center Holdings, Inc. v. WCE CA Art, LLC (Cal. Ct. App., 2d Dist.), arguing that a nonprofessional corporation with the right to replace a PC’s physician-owner exercises impermissible control over the practice. On May 7, 2026, the AG announced a $2M-plus settlement with Aspen Dental resolving corporate-practice-of-dentistry allegations and imposing structural conditions on the MSO. And on June 26, 2026, the AG announced the settlement that changed the analysis for non-licensee individuals: Carbon Health Technologies, its affiliated professional corporations, and co-founder and former CEO Eren Bali.

The Carbon Health judgment (subject to court approval) imposes $4.4 million in civil penalties against the Carbon Health entities plus a $100,000 civil penalty against Mr. Bali personally. It permanently enjoins several MSA arrangements the AG considers impermissible, including: assignable option agreements giving the MSO the right to acquire the PC’s ownership interests; complete MSO authority over advertising, payor negotiations, equipment selection, and the hiring, firing, and compensation of clinicians; and exclusive above-market financing arrangements the AG considers instruments of control rather than ordinary financing tools.

Two takeaways for a non-licensee buyer. First, the AG has now demonstrated that CPOM enforcement can reach an individual founder or officer personally, not just the operating entities. Second, the AG has published its list of MSA provisions it considers problematic. Buyers using inherited MSA templates from a franchise system, a national platform, or an out-of-state formation service now have a benchmark to check against.

Building the Compliant Deal: A Practical Sequence

A non-licensee acquisition of a California treatment business generally moves through the following steps. Some can compress or overlap depending on complexity; none should be skipped.

Pre-LOI: identify a physician-partner and confirm the target is acquirable. The physician-partner is not a post-LOI logistical detail; the physician-partner determines whether the deal can happen at all. Before the LOI, the buyer should have a specific physician identified, willing to hold the PC that will emerge from the transaction, and aligned on the compensation, governance, and buy-sell terms. In parallel, buyer’s counsel confirms the target is legally acquirable — CPOM analysis of the seller’s existing structure, review of the seller’s operating history for historical exposure that would follow into the buyer’s arrangement, and identification of any pending regulatory or payor issues.

LOI: fix the deal structure in writing. The LOI should specify that the transaction is an asset purchase (not a stock purchase of the seller’s PC or LLC), the bifurcation of clinical assets (going to the newly formed physician PC) from non-clinical assets (going to the MSO), the physician-partner’s identity and role, and the deal timeline including any AB 1415 notice window. It should also allocate CPOM-diligence risk between buyer and seller.

Diligence: CPOM-focused. Beyond standard M&A diligence (financials, contracts, employment, IP, tax, litigation), CPOM diligence focuses on: whether the target has a physician-owned PC in place at all; the medical director arrangement (paper vs. actual); the good-faith exam workflow; the standardized procedures for RN-delegated functions under 16 CCR § 1474; the licensure and DEA status of clinical staff; the Fictitious Name Permit status under B&P § 2415; the fee arrangement with any existing medical director; historical direct-to-patient billing by an entity not authorized to render medical services; and marketing representations that could give rise to § 17200 exposure.

PC formation and MSA drafting. The physician-partner forms the professional corporation (Articles of Incorporation ARTS-PC, Statement of Information SI-550, Fictitious Name Permit if operating under a brand name, employer identification and payroll registration, FTB minimum-tax planning). Buyer’s counsel drafts the Management Services Agreement, coordinating with the buyer’s CPA on FMV support for the management fee and with the physician partner’s counsel on the PC’s clinical control provisions.

Bifurcated asset transfer. Clinical assets — patient records, clinical goodwill, clinical equipment, provider agreements — transfer to the newly formed PC. Non-clinical assets — trade name (with proper Fictitious Name Permit), systems, non-clinical equipment, leasehold, marketing IP — transfer to the MSO. The transfer is documented as a taxable asset purchase; the buyer’s CPA coordinates purchase-price allocation.

Payor and licensure transitions. For targets with meaningful payor enrollment, buyer’s counsel coordinates the Medicare change-of-ownership analysis under 42 C.F.R. § 489.18, the Medi-Cal and commercial payor consents and novations, and the DEA registration transitions if the practice involves controlled substances. Most cash-pay treatment businesses have limited payor enrollment, which materially simplifies the transition — but does not exempt the transaction from CPOM compliance.

Post-closing operational discipline. The friendly-PC + MSO structure works over time because the parties maintain the separation the MSA documents: separate books and bank accounts; PC control over clinical decisions, patient records, and clinician hiring and firing; annual FMV refresh of the management fee; and an operating discipline that survives changes in ownership, growth, and market pressure. The most common source of post-closing CPOM exposure is not defective initial documentation; it is drift.

Common Buyer Misconceptions Worth Correcting

“The seller already has an MD who will stay on.” Verify. Confirm the physician’s licensure status, whether the physician is a shareholder of an existing PC (and, if so, whether that PC will remain in place or be replaced), the physician’s actual role in the practice (not the physician’s paper role), and the physician’s willingness to be the shareholder of the PC going forward on terms the buyer can live with.

“It’s all cash pay so CPOM doesn’t apply.” CPOM is a licensing doctrine, not a payor doctrine. It applies regardless of whether the practice bills insurance, cash, membership fees, or a combination. The Carbon Health settlement expressly addressed billing and consumer-protection issues alongside CPOM — the AG did not treat cash-pay operations as exempt from either analysis.

“I’ll just buy the LLC and keep operating.” An LLC cannot render medical services in California under Cal. Corp. Code § 17701.04(e). Continuing to operate through a purchased LLC that has been treating patients extends the seller’s historical CPOM exposure to the buyer and adds new post-closing exposure to the buyer’s own operation.

“The franchise system’s MSA is compliant everywhere.” Not necessarily. MSA templates that work in Texas, Florida, or Delaware often fail California’s CPOM analysis under Epic / B&P § 650(b), and post–January 1, 2026, may run into SB 351’s specific contract restrictions. California-specific counsel review is not optional.

“I’ll form the PC after closing to keep things simple.” The PC has to be in place before closing so the clinical assets can transfer into a valid legal owner. Post-closing formation creates a gap in which the buyer’s MSO has acquired clinical assets it cannot legally hold.

When to Bring Counsel Into the Deal

Before the LOI is signed, before earnest money is released, and before the buyer relies on any representation from the seller that “the structure is already set up correctly.” Once the LOI is signed and diligence is underway, deal timing pressures compress the CPOM analysis and physician-partner negotiation into windows that are shorter than the work requires.

Bay Legal, PC represents non-licensee buyers of California treatment businesses across the full deal cycle. For guidance on your specific situation, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.

Frequently Asked Questions

Can I buy a med spa or IV hydration clinic in California if I am not a doctor?

Yes, but not through a direct purchase of the seller’s entity if that entity is a professional corporation, and not by continuing to operate through the seller’s LLC if the LLC has been treating patients. The compliant path is an asset purchase in which a licensed physician acquires the clinical assets into a newly formed physician-owned professional corporation, and your management entity acquires the non-clinical assets and provides services to the PC under a Management Services Agreement.

Do I need to find a physician-partner before I sign the LOI?

Effectively, yes. The physician-partner’s willingness to hold the PC and the terms on which the physician participates are integral to whether the deal actually closes on a compliant structure. Buyers who defer the physician-partner search until after LOI often find that closing timelines outrun the physician negotiation.

What is a friendly-PC + MSO structure?

A two-entity structure in which a physician-owned professional corporation delivers clinical care and holds patient records, and a separately-owned management services organization (typically an LLC) provides non-clinical administrative and operational support under a Management Services Agreement. The physician holds and controls the PC; the operator or investor holds the MSO; the MSA governs the fee, the operational separation, and the change-of-control mechanics.

Does the AB 1415 90-day OHCA notice apply to my deal?

It depends on the deal structure, the acquisition vehicle, and the capital source. Single-clinic acquisitions by an individual buyer or a family office without private equity or hedge fund participation typically will not trigger notice under current proposed OHCA thresholds. Deals involving PE or hedge fund capital, acquisition vehicles rolling up multiple locations, or MSO-to-MSO transactions may. Confirm current OHCA regulation status at hcai.ca.gov before finalizing deal timing.

What is the practical exposure if I close a non-compliant deal?

Exposure varies with facts and enforcement posture. Categories include: contract voidability of MSAs and other transaction documents; civil penalties under the Unfair Competition Law (B&P § 17200); Medical Board disciplinary exposure for the physician-of-record; payor recoupment for practices with meaningful payor enrollment; consumer-protection and false-advertising claims; and, as the Carbon Health settlement demonstrated, personal civil penalties against non-licensee owners and officers. Voluntary pre-closing structuring is materially better than reactive post-closing remediation.

Talk to a California Healthcare Acquisition Attorney

Bay Legal, PC represents non-licensee buyers of California treatment businesses from target-identification through post-closing integration. If you are evaluating a target, negotiating an LOI, or closing on a deal, we can help you structure the transaction for CPOM compliance and long-term operational discipline. For guidance on your specific situation, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.